Follow

Board of Directors and management of Prostatype Genomics AB enter into agreements regarding lock up

27 October 2021 - 10:00

Prostatype Genomics AB (“Prostatype” or “the Company”) hereby announces that members of the Board and management of the Company have entered into agreements regarding prolonged lock up of their holdings in the Company. The lock up refers to 100 percent of each of the parties’ holdings, for a period lasting until the 30th of April 2022.

In connection with the IPO of Prostatype, members of the Board, as well as management and other shareholders entered into agreement regarding lock up. These agreements expire on the 3rd of November 2021, which is 12 months after the first day of trading in Prostatype’s shares and warrants on Nasdaq First North Growth Market.

The Board of Directors as well as management have now, based on that the original agreements will expire shortly, entered into prolonged agreements regarding lock up. The parties who have entered into the agreements are Creathor Venture Fund III (SCS) SICAR, Creathor Venture Fund III Parallel (SCS) SICAR, Board members Håkan Englund, Michael Häggman, Anders Lundberg, CEO Fredrik Persson and CFO Michael af Winklerfelt. Together, these shareholders own approximately 30 percent of the total shares in the Company.


This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-10-2021 10:00 CET.

Press contact

Nicklas Rosendal
[email protected]

Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, [email protected]

Provided by: Cision
Nasdaq First North GM (Sweden)
Prostatype Genomics AB
Prostatype Genomics manufactures, markets and sells the prognostic gene test Prostatype. By giving a assessment of the aggressiveness of the prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More